MarketCap
Facebook
X
Telegram
Amicus Therapeutics Operating Cash Flow | FOLD
Annual Operating Cash Flow Amicus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.1 M | -33.9 M | -69.1 M | -167 M | -202 M | -233 M | -250 M | -300 M | -214 M | -150 M | -100 M | - | - | - | -49.4 M | -14 M | -43.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.1 M | -300 M | -128 M |
Quarterly Operating Cash Flow Amicus Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.1 M | -23 M | 22.7 M | -29.7 M | - | - | - | -29.7 M | - | - | - | -18.1 M | - | -85.8 M | - | -58.3 M | - | -132 M | - | -72.4 M | - | -183 M | -141 M | -108 M | - | -193 M | -137 M | -78.5 M | - | -239 M | -107 M | -49.5 M | - | -141 M | -91.8 M | -49.8 M | - | -119 M | -77.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.7 M | -239 M | -90.8 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-13.9 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
-16.7 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
66.5 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Corner Growth Acquisition Corp.
COOL
|
-21.6 K | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Qilian International Holding Group Limited
QLI
|
-2.37 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
-1.4 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-12.9 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
102 M | - | - | $ 867 M |  Germany |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
28.7 M | - | - | $ 4.9 B |  Britain |
|
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-3.27 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-88.2 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-296 M | - | 2.43 % | $ 254 M | Germany |
 |
Codexis
CDXS
|
-19.4 M | $ 1.46 | 2.82 % | $ 127 M | USA |
 |
Ardelyx
ARDX
|
-42.5 M | $ 3.78 | 1.89 % | $ 911 M | USA |
 |
Affimed N.V.
AFMD
|
-110 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 23.9 | 1.01 % | $ 3.04 B | USA |
 |
Assembly Biosciences
ASMB
|
-41.1 M | $ 36.6 | 1.3 % | $ 410 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-55.1 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-6.49 M | $ 7.12 | 6.91 % | $ 4.76 M | USA |
 |
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-483 M | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 206.68 | 0.16 % | $ 10.3 B | USA |
 |
GlycoMimetics
GLYC
|
-71.5 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
19.7 M | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-60.1 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 66.53 | 0.15 % | $ 12.8 B | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Bicycle Therapeutics plc
BCYC
|
-250 M | $ 4.3 | 1.42 % | $ 298 M | Britain |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
ChromaDex Corporation
CDXC
|
13.5 M | - | -0.88 % | $ 598 M | USA |